Recurrence Rate for Triple Negative Breast Cancer

Breast cancer is not a disease, but it consists of several subtypes. One of these subtypes is called Triple Negative Breast Cancer (TNBC). TNBC does not respond to hormone estrogen, progesterone or HER2 / neu. Therefore, TNBC does not respond to hormone therapy against these hormone receptors. In this type of breast cancer, target treatment can not be done like other breast cancer subtypes.

According to a survey by Johns Hopkins Breast Center, about 10% to 20% of people diagnosed with breast cancer have triple negative subtypes. TNBC is growing rapidly. It also has a higher level and tends to shift (spread)

Because cancer grows rapidly, it is common in mammograms. However, the rapid growth rate means that standard chemotherapy is more likely to induce remission

Recurrence is also called recurrence, breast cancer recurrence. Breast cancer may recur locally in the breast or scar tissue, or may recur in the remote part of the body, including other parts of the body, including bones and organs. Cancer that develops distally is considered a metastatic cancer. It is not incurable, but it is very difficult to stop this

TNBC characteristically has a high recurrence rate, which drops sharply after 5 years. According to modern oncology, about 34% of women experience a remote recurrence with an average of 6 years of relapse.

The recurrence risk of TNBC was the greatest in the first 3 years and declined rapidly after 5 years. Therefore, there is no long-term treatment plan after treatment

This shows a hidden advantage: shortening of the treatment process. Females with early growth ER + cancer are usually treated more than 10 years

TNBC 5-year survival is often lower than other types of breast cancer. This means that the risk of death is high when cancer recurs. According to BreastCancer.org, the 5-year survival rate of TNBC is about 77%, but the survival rate of other types of breast cancer is 93%.

The survival rate of a person depends on many factors. This includes the stage and malignancy of cancer, and your response to treatment. Remember that, like all cancers, each person's prognosis is unique. Statistics apply to groups, not individuals

TNBC can be treated by surgery, radiation therapy and chemotherapy. New therapies such as polymerase (PARP) enzyme inhibitors are promising. If diagnosed as TNBC, you can also consider clinical trials to increase treatment options.

Continuing to schedule regular reservations is very important. Please manage your health with appropriate diet and exercise. Meditation also helps to find an emotional balance during this time.

Support groups and treatments help to relieve anxiety and provide tools to manage uncertainty.

Some people think that TNBC cancer rarely recurs after 5 years, and it has become cancer.

Triple negative breast cancer is negative for estrogen receptor, negative for progesterone receptor, and negative for HER2. Even if you use hormone therapy or HER 2 medication, you will not delay these invasive cancers. Triple negative breast cancer is more common not only for young women but also for Hispanic and African American women. Also known as precancerous, this is the early stage of breast cancer. The abnormal cells in which it is involved have not yet spread to the breast tissue from ducts or leaflets where they started. Breast cancer in stage 0 did not spread to lymph nodes or other parts of the body. Stage 0 breast cancer such as epithelial epithelial cancer (DCIS) is noninvasive

Triple negative breast cancer (TNBC) accounts for approximately 15% of all breast cancers. This type of breast cancer is called triple negative because tumor cells lack expression of the estrogen receptor (ER), progesterone receptor (PR), or HER2 receptor. Due to the heterogeneity of target therapy diseases, the treatment of TNBC is more complicated, which means that each TNBC is unique in its cell and gene composition.

However, some breast cancer patients lack these receptors. When this occurs breast cancer is called triple negative. And, without any receptors, the treatment can be more challenging. That is why Triple Negative Breast Cancer (TNBC) is one of the cancers we care about and we can greatly reduce cancer mortality as part of the Moon Shot program. Three negative patients are more likely to have a BRCA1 or BRCA2 gene mutation than non TNBC patients. However, even without BRCA1 or BRCA2 mutations, there is the possibility of developing triple negative breast cancer. We are still trying to understand the relationship between triple negative breast cancer and BRCA.